Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementa
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Both Alzheimer's disease and senile dementia of the Alzheimer type (AD/SDAT) are progressive dementias characterized neuropathologically by the presence in the cerebral cortex of numerous neurofibrillary tangles and neuritic plaques. We use the abbreviation AD/SDAT to denote all such cases, irrespective of age of onset. Studies of neurotransmitter-related parameters in autopsied brain tissues from patients with AD/SDAT have, to date, been confined to five putative transmitter systems. Acetycholine-releasing neurones seem to be most markedly and consistently affected, as judged by the extensive reductions in choline acetyltransferase (ChAT) and acetylcholinesterase activities that have been reported. Despite numerous studies, there is no consistent evidence for the involvement of neurones releasing dopamine, noradrenaline, serotonin, or gamma-aminobutyric acid in AD/SDAT, nor for loss of muscarinic cholinergic receptors. Thus, the involvement of cholinergic neurones in AD/SDAT seems to be specific. However, the possible involvement of neurones using other chemicals as transmitters has yet to be explored. The recent recognition of the existence of so-called 'peptidergic neurones' in the mammalian brain (for review see ref. 8) and the availability of radioimmunoassay (RIA) techniques for studying these peptides, have led us to begin a systematic investigation of neuropeptides in autopsied brain tissue from cases of AD/SDAT, and from neurologically normal individuals. We report here results obtained with a RIA for somatostatin, showing that somatostatin-like immunoreactivity in the cerebral cortex is reduced in tissue from AD/SDAT patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Aβ not only affects intracellular vesicular trafficking but could also affect primary cilia function directly or indirectly via its cognate binding receptors such as LRP1 [15, 50, 75].”
From Abnormal accumulation of extracellular vesicles in hippocampal dystrophic axons and regulation by the primary cilia in Alzheimer's disease (2023) · cites this paper as [15]
In the citing paper
“In addition, SST administration has been shown to be effective in improving cognitive impairment in AD patients [12, 15].”
From Abnormal accumulation of extracellular vesicles in hippocampal dystrophic axons and regulation by the primary cilia in Alzheimer's disease (2023) · cites this paper as [15]
In the citing paper
“Dysfunctional SOMs have been identified as a hallmark of AD, and loss of SOMs in the cortex is associated with AD pathologies [10, 15, 65].”
From Abnormal accumulation of extracellular vesicles in hippocampal dystrophic axons and regulation by the primary cilia in Alzheimer's disease (2023) · cites this paper as [15]
In the citing paper
“Additionally, AD patients have a specific loss of somatostatin-positive interneurons in the cortex [94] and hippocampus [95].”
From Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease (2019) · cites this paper as [94]
Citations
Cites
Hökfelt, T., Johansson, O., Ljungdahl, Å., Lundberg, J. M., & Schultzberg, M. (1980) · Nature · doi:10.1038/284515a0 · Cited by 1,547
NECROPSY EVIDENCE OF CENTRAL CHOLINERGIC DEFICITS IN SENILE DEMENTIA
Perry, E., Perry, R., Blessed, G., & Tomlinson, B. (1977) · The Lancet · doi:10.1016/s0140-6736(77)91780-9 · Cited by 1,069
Neurotransmitter-related enzymes in senile dementia of the alzheimer type
Davies, P. (1979) · Brain Research · doi:10.1016/0006-8993(79)90336-6 · Cited by 634
Self-citationThe Prevalence and Malignancy of Alzheimer Disease: A Major Killer
Katzman, R. (1976) · Archives of Neurology · doi:10.1001/archneur.1976.00500040001001 · Cited by 619
Self-citationDementia of the Alzheimer Type
Terry, R. D., & Davies, P. (1980) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.03.030180.000453 · Cited by 529
Self-citationPrevalence and Malignancy of Alzheimer Disease
Lijtmaer, H., Fuld, P. A., & Katzman, R. (1976) · Archives of Neurology · doi:10.1001/archneur.1976.00500040088017 · Cited by 517
Self-citationNEOCORTICAL CHOLINERGIC NEURONS IN ELDERLY PEOPLE
White, P., Goodhardt, M. J., Keet, J. P., Hiley, C. R., Carrasco, L. H., Williams, I. E. I., & Bowen, D. M. (1977) · The Lancet · doi:10.1016/s0140-6736(77)92114-6 · Cited by 489
Davies, P., & Verth, A. H. (1977) · Brain Research · doi:10.1016/0006-8993(77)90758-2 · Cited by 313
Self-citationRadioimmunoassay for GH-Release Inhibiting Hormone
Arimura, A., Sato, H., Coy, D. H., & Schally, A. V. (1975) · Experimental Biology and Medicine · doi:10.3181/00379727-148-38631 · Cited by 302
Research works printed but not linked: 1
- Wisniewski, H. M. & Terry, R. D. in Neurobiology of Aging (eds Terry, R. D. & Gershon, S.) 265–280 (Raven, New York, 1976).
Cited by
Items 301–400 of 889
Duclot, F., Meffre, J., Jacquet, C., Gongora, C., & Maurice, T. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.02.055 · Cited by 58
Peineau, S., Rabiant, K., Pierrefiche, O., & Potier, B. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.01.018 · Cited by 60
Evidence for retrograde degeneration of epinephrine neurons in Alzheimer's disease
Burke, W. J., Chung, H. D., Huang, J. S., Huang, S. S., Haring, J. H., Strong, R., Marchshall, G. L., & Joh, T. H. (1988) · Annals of Neurology · doi:10.1002/ana.410240409 · Cited by 55
Somatostatin in the dentate gyrus
Tallent, M. K. (2007) · Progress in brain research · doi:10.1016/s0079-6123(07)63016-7 · Cited by 57
Neuropeptide effects on memory in aged monkeys
Bartus, R. T., Dean, R. L., & Beer, B. (1982) · Neurobiology of Aging · doi:10.1016/0197-4580(82)90062-8 · Cited by 54
Reinikainen, K. J., Riekkinen, P. J., Jolkkonen, J., Kosma, V.-M., & Soininen, H. (1987) · Brain Research · doi:10.1016/0006-8993(87)91052-3 · Cited by 54
Mufson, E. J., Kehr, A. D., Wainer, B. H., & Mesulam, M. M. (1987) · Brain Research · doi:10.1016/0006-8993(87)90470-7 · Cited by 54
Katsuki, F., Gerashchenko, D., & Brown, R. E. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2022.07.002 · Cited by 52
Ádori, C., Glück, L., Barde, S. S., Yoshitake, T., Kovács, G. G., Mulder, J., Maglóczky, Z., Havas, L., Bölcskei, K., Mitsios, N., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1394-3 · Cited by 57
“Another, early established neurochemical hallmark of Alzheimer’s disease is a substantial deficit of somatostatin (SST) in cortical areas and in the hypothalamus [20, 27, 58, 76, 89].”
BackgroundBiological substrates underpinning diagnosis of major depression
Sibille, E., & French, B. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000436 · Cited by 50
“…(Morris et al., 2008), bipolar disorder (Konradi et al., 2004, 2010) and in Huntington’s (Timmers et al., 1996), Alzheimer’s (reviewed in Davies et al., 1980; Epelbaum et al., 2009) and Parkinson’s diseases (reviewed in Epelbaum et al., 1989), although in the context of additional…”
BackgroundNeuropeptides: Roles and Activities as Metal Chelators in Neurodegenerative Diseases
Ben-Shushan, S., & Miller, Y. (2021) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.0c11151 · Cited by 54
Neuropeptides in Alzheimer's disease: a postmortem study
Nemeroff, C. B., Kizer, J. S., Reynolds, G. P., & Bissette, G. (1989) · Regulatory Peptides · doi:10.1016/0167-0115(89)90254-1 · Cited by 59
Dissociation of neuropeptide Y and somatostatin in Parkinson's disease
Allen, J. M., Cross, A. J., Crow, T. J., Javoy-Agid, F., Agid, Y., & Bloom, S. R. (1985) · Brain Research · doi:10.1016/0006-8993(85)91632-4 · Cited by 57
Spinal fluid CRF reduction in Alzheimer's disease
Mouradian, M. M., Farah, J. M., Mohr, E., Fabbrini, G., O’Donohue, T. L., & Chase, T. N. (1986) · Neuropeptides · doi:10.1016/0143-4179(86)90010-7 · Cited by 53
Alzheimer's Disease, Neuropeptides, Neuropeptidase, and Amyloid-β Peptide Metabolism
Saito, T., Takaki, Y., Iwata, N., Trojanowski, J. Q., & Saido, T. C. (2003) · Science of Aging Knowledge Environment · doi:10.1126/sageke.2003.3.pe1 · Cited by 59
Glutamate Neurotoxicity, Calcium, and Zinca
Choi, D. W., Weiss, J. H., Koh, J., Christine, C. W., & Kurth, M. (1989) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1989.tb12511.x · Cited by 54
Changes in brain somatostatin in memory-deficient rats: comparison with cholinergic markers
Matsuoka, N., Yamazaki, M., & Yamaguchi, I. (1995) · Neuroscience · doi:10.1016/0306-4522(94)00628-i · Cited by 58
Casello, S. M., Flores, R. J., Yarur, H. E., Wang, H., Awanyai, M., Arenivar, M. A., Jaime-Lara, R. B., Bravo-Rivera, H., & Tejeda, H. A. (2022) · Frontiers in Neural Circuits · doi:10.3389/fncir.2022.796443 · Cited by 54
Ik, C., Lee, Y. I., Lee, E. Y., Park, K. H., & Baik, S. H. (1997) · Brain Research · doi:10.1016/s0006-8993(97)00009-7 · Cited by 52
Developing Preventive Therapies for Chronic Diseases: Lessons Learned from Alzheimer's Disease
Selkoe, D. J. (2008) · Nutrition Reviews · doi:10.1111/j.1753-4887.2007.tb00370.x · Cited by 50
Carboni, A. A., Lavelle, W. G., Barnes, C. L., & Cipolloni, P. B. (1990) · The Journal of Comparative Neurology · doi:10.1002/cne.902910407 · Cited by 51
A comparison of somatostatin and neuropeptide Y distribution in monkey brain
Beal, M. F., Mazurek, M. F., & Martin, J. B. (1987) · Brain Research · doi:10.1016/0006-8993(87)90290-3 · Cited by 50
Excitability and Synaptic Alterations in the Cerebellum of APP/PS1 Mice
Hoxha, E., Boda, E., Montarolo, F., Parolisi, R., & Tempia, F. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034726 · Cited by 52
“In fact, AD patients have decreased GABA or somatostatin levels in the brain and cerebrospinal fluid [32–37].”
BackgroundForloni, G., Lucca, E., Angeretti, N., Chiesa, R., & Vezzani, A. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.68010319.x · Cited by 49
“For instance, a depletion of SRIF in the cerebral cortex associated with cholinergic deficits neurochemically characterizes Alzheimer’s brains (Davies et al., 1980; Mazurek and Beal, 1991), whereas selective sparing of striatal SRIF-containing neurons was observed in Huntington’sdisease (Ferrante…”
BackgroundSchettini, G., Florio, T., Magri, G., GRIMALDI, M., Meucci, O., Landolfi, E., & Marino, A. (1988) · European Journal of Pharmacology · doi:10.1016/0014-2999(88)90536-5 · Cited by 52
Song, Y.-H., Hwang, Y.-S., Kim, K., Lee, H., Kim, J., Maclachlan, C., Dubois, A., Jung, M. W., Petersen, C. C. H., Knott, G. W., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz0517 · Cited by 51
Gleichmann, M., Zhang, Y., Wood, W. H., Becker, K. G., Mughal, M. R., Pazin, M. J., van Praag, H., Kobilo, T., Zonderman, A. B., Troncoso, J. C., et al. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.08.012 · Cited by 46
“Even though somatostatin has long been recognized as an inhibitory neuropeptide that is downregulated in AD (Beal, 1990; Davies et al., 1980) and activitydependently expressed (Montminy and Bilezikjian, 1987), a theory of homeostatic disinhibition in the aging brain and in AD has not been formulated.”
BackgroundMoore, S. D., Madamba, S. G., & Siggins, G. R. (1990) · Brain Research · doi:10.1016/0006-8993(90)90922-x · Cited by 51
Chapter 9 The neuropeptide concept
de Wied, D. (1987) · Progress in brain research · doi:10.1016/s0079-6123(08)60199-5 · Cited by 53
Mufson, E. J., Benoit, R., & Mesulam, M. M. (1988) · Brain Research · doi:10.1016/0006-8993(88)90149-7 · Cited by 48
Distribution of somatostatin immunoreactivity in the human dentate gyrus
Amaral, D., Insausti, R., & Campbell, M. (1988) · Journal of Neuroscience · doi:10.1523/jneurosci.08-09-03306.1988 · Cited by 50
“Biochemical studies have shown that there is both a decrease in somatostatin content (Davies et al., 1980; Rossor et al., 1980; Davies and Terry, 198 1; Beal et al., 1986) and receptors (Beal et al., 1985) in the hippocampal formation and neocortex.”
Neuropeptides in aging and dementia
Joynt, R. J., & McNeill, T. H. (1984) · Peptides · doi:10.1016/0196-9781(84)90286-9 · Cited by 50
Galanin mRNA in the nucleus basalis of Meynert complex of baboons and humans
Walker, L. C., Rance, N. E., Price, D. L., & Young, W. S. (1991) · Journal of Comparative Neurology · doi:10.1002/cne.903030110 · Cited by 48
Metabolism of amyloid β peptide and pathogenesis of Alzheimer’s disease
Saido, T. C. (2013) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.89.321 · Cited by 59
Ontogeny of somatostatin in cerebral cortex of macaque monkey: an immunohistochemical study
Yamashita, A., Hayashi, M., Shimizu, K., & Oshima, K. (1989) · Developmental Brain Research · doi:10.1016/0165-3806(89)90012-6 · Cited by 47
Philothermal response of polymorphonuclear leukocytes in dementia of the Alzheimer type
Jarvik, L. F., Matsuyama, S. S., Kessler, J. O., Fu, T.-K., Tsau, S. Y., & Clark, E. O. (1982) · Neurobiology of Aging · doi:10.1016/0197-4580(82)90002-1 · Cited by 47
Unger, J. W., McNeill, T. H., Lapham, L. L., & Hamill, R. (1988) · Brain Research · doi:10.1016/0006-8993(88)90033-9 · Cited by 49
Human cerebrospinal fluid somatostatin in neurologic disease
Beal, M. F., Mazurek, M. F., Black, P. M., & Martin, J. B. (1985) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(85)90039-5 · Cited by 47
Somatostatin binds to the human amyloid β peptide and favors the formation of distinct oligomers
Wang, H., Muiznieks, L. D., Ghosh, P., Williams, D., Solarski, M., Fang, A., Ruiz‐Riquelme, A., Pomès, R., Watts, J. C., Chakrabartty, A., et al. (2017) · eLife · doi:10.7554/elife.28401 · Cited by 52
“Several observations stand out amongst the connections of SST to AD and should be considered in future efforts to understand the possible significance of the direct interaction between SST and Ab1-42: (1) Already in 1980, it was observed that SST levels are conspicuously reduced in AD-afflicted brains (Davies et al.,…”
ResultCerebrospinal fluid neuropeptides in Alzheimer's disease and vascular dementia
Heilig, M. A., Sjögren, M. J. C., Blennow, K., Ekman, R., & Wallin, A. (1995) · Biological Psychiatry · doi:10.1016/0006-3223(94)00239-y · Cited by 47
Aging and Alzheimer Disease in People with Mental Retardation
Zigman, W. B., Schupf, N., Zigman, A., & Silverman, W. P. (1993) · International review of research in mental retardation · doi:10.1016/s0074-7750(08)60188-3 · Cited by 46
Somatostatin Localization in Tissues
Polak, J. M., & Bloom, S. R. (1986) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365528609087427 · Cited by 53
Chase, T. N., Burrows, G. H., & Mohr, E. (1987) · Archives of Gerontology and Geriatrics · doi:10.1016/0167-4943(87)90028-8 · Cited by 47
Role of the somatostatin system in contextual fear memory and hippocampal synaptic plasticity
Kluge, C., Stoppel, C. M., Szinyei, C., Stork, O., & Pape, H. (2008) · Learning & Memory · doi:10.1101/lm.793008 · Cited by 53
“2000, 2003) and recently also in the pathology of Alzheimer’s disease (Davies et al. 1980; Saito et al. 2005), an ailment in which hippocampal memory deficits are a prominent clinical feature.”
BackgroundDanielsson, E., Eckernäs, S.-K., Westlind‐Danielsson, A., Nordström, Ö., Bartfai, T., Gottfries, C., & Wallin, A. (1988) · Neurobiology of Aging · doi:10.1016/s0197-4580(88)80045-9 · Cited by 46
Aso, E., Andrés‐Benito, P., & Ferrer, I. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.08.007 · Cited by 48
Saiz-Sanchez, D., Ubeda-Bañon, I., De la Rosa-Prieto, C., & Martinez-Marcos, A. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-111889 · Cited by 45
Woodruff‐Pak, D. S., & Thompson, R. F. (1985) · Experimental Aging Research · doi:10.1080/03610738508259290 · Cited by 46
Neurochemical characteristics of aluminum-induced neurofibrillary degeneration in rabbits
Beal, M. F., Mazurek, M. F., Ellison, D. W., Kowall, N. W., Solomon, P. R., & Pendlebury, W. W. (1989) · Neuroscience · doi:10.1016/0306-4522(89)90061-4 · Cited by 45
Brain choline acetyltransferase activity and neuropeptide Y concentrations in Alzheimer's disease
Foster, N. L., Tamminga, C. A., O’Donohue, T. L., Tanimoto, K., Bird, E. D., & Chase, T. N. (1986) · Neuroscience Letters · doi:10.1016/0304-3940(86)90015-7 · Cited by 47
Animal Models of Alzheimer's Disease: Behavior, Pharmacology, Transplants
Haroutunian, V. H., Kanof, P. D., Tsuboyama, G. K., Campbell, G. A., & Davis, K. L. (1986) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100036957 · Cited by 46
Consens, M. E., Chen, Y., Menon, V., Wang, Y., Schneider, J. A., De Jager, P. L., Bennett, D. A., Tripathy, S. J., & Felsky, D. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.903175 · Cited by 44
“The association of SST with AD is decades-old, beginning with seminal 402 findings reporting reduced levels of somatostatin immunoreactivity in AD brain [35], and more 403 recently with cross-study differential expression analyses finding ubiquitous reductions of SST 404 RNA in AD brain tissue (with the exception of t…”
BackgroundInterneurons in the human olfactory system in Alzheimer's disease
Saiz‐Sánchez, D., Flores‐Cuadrado, A., Úbeda‐Bañón, I., de la Rosa‐Prieto, C., & Martínez-Marcos, A. (2015) · Experimental Neurology · doi:10.1016/j.expneurol.2015.11.009 · Cited by 47
Zhang, Z.-J., Lappi, D. A., Wrenn, C. C., Milner, T. A., & Wiley, R. G. (1998) · Brain Research · doi:10.1016/s0006-8993(98)00484-3 · Cited by 44
Trujillo-Estrada, L., Jimenez, S., De Castro, V., Torres, M., Baglietto-Vargas, D., Moreno-Gonzalez, I., Navarro, V., Sanchez-Varo, R., Sanchez-Mejias, E., Davila, J. C., et al. (2013) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-1-73 · Cited by 44
“These GABAergic cells are implicated in memory/learning processes and degenerate in AD patients [25,26].”
BackgroundSomatostatin immunoreactivity in cortical and some subcortical regions in Alzheimer's disease
Candy, J. M., Gascoigne, A. D., Biggins, J. A., Smith, A. I., Perry, R. H., Perry, E. K., MCDERMOTT, J. R., & Edwardson, J. A. (1985) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(85)90070-x · Cited by 45
Possible Role(s) of Neurokinins in CNS Development and Neurodegenerative or Other Disorders
Raffa, R. B. (1998) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(97)00070-5 · Cited by 46
Tong, L. M., Yoon, S. Y., Andrews-Zwilling, Y., Yang, A., Lin, V., Lei, H., & Huang, Y. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.3815-15.2016 · Cited by 43
“Decreases in SST have also been associated with AD in humans (Davies et al., 1980), particularly so among apoE4 carriers (Grouselle et al., 1998).”
BackgroundTreatment of dementia with neurotransmission modulation
Doggrell, S. A., & Evans, S. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.10.1633 · Cited by 48
“The cerebrocortical cholinergic system and somatostatin-containing neuronal systems are greatly reduced in AD [4,5].”
BackgroundEbinger, G., Bruyland, M., Martin, J. J., Herregodts, P., Cras, P. P., Michotte, Y. M., & Gommé, L. (1987) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(87)90128-6 · Cited by 45
Clinical Studies of the Cholinergic Deficit in Alzheimer's Disease
Mohs, R. C., Davis, B. M., GREENWALD, B. S., Mathé, A. A., Johns, C. A., Horvath, T., & Davis, K. L. (1985) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1985.tb04185.x · Cited by 43
Present state and future development of the therapy of Alzheimer disease
Pomponi, M. F. L., Giacobini, E., & Brufani, M. (1990) · Aging Clinical and Experimental Research · doi:10.1007/bf03323906 · Cited by 59
A comparison of regional somatostatin and neuropeptide Y distribution in rat striatum and brain
Beal, M. F., Chattha, G. K., & Martin, J. B. (1986) · Brain Research · doi:10.1016/0006-8993(86)90864-4 · Cited by 44
Sakurada, T., Alufuzoff, I., Winblad, B. G., & Nordberg, A. K. (1990) · Brain Research · doi:10.1016/0006-8993(90)91561-t · Cited by 43
Epelbaum, J., Dussaillant, M., Enjalbert, A., Kordon, C., & Rostène, W. H. (1985) · Peptides · doi:10.1016/0196-9781(85)90177-9 · Cited by 43
Endogenous modulation of ACh release by somatostatin and the differential roles of Ca2+ channels
Db, G., Zelazny, D., MANTHAY, N., & Pilar, G. (1990) · Journal of Neuroscience · doi:10.1523/jneurosci.10-08-02687.1990 · Cited by 42
“Also, Alzheimer's patients show a diminution of cholinergic innervation and somatostatin levels (Davies, 1979; Davies et al., 1980).”
Substance P immunoreactivity within neuritic plaques
Armstrong, D. M., & Terry, R. D. (1985) · Neuroscience Letters · doi:10.1016/0304-3940(85)90343-x · Cited by 42
Self-citationInteractions between cholinergic and peptidergic systems in the cerebral cortex and hippocampus
Lamour, Y. A., & Epelbaum, J. (1988) · Progress in Neurobiology · doi:10.1016/0301-0082(88)90029-9 · Cited by 45
Waller, R., Mandeya, M., Viney, E., Simpson, J. E., & Wharton, S. B. (2020) · Neuropathology · doi:10.1111/neup.12649 · Cited by 44
“AD (9 hippocampus blocks, 9 temporal cortex blocks) 75 (59-93) (5/4) 62 (24-96) Alzheimer’s Disease”
Acetylcholine dramatically increases prostanoid synthesis in piglet parietal cortex
Busija, D. W., Wagerle, L. C., Pourcyrous, M., & Leffler, C. W. (1988) · Brain Research · doi:10.1016/0006-8993(88)91468-0 · Cited by 41
Haroutunian, V. H., Santucci, A. C., & Davis, K. L. (1990) · Progress in brain research · doi:10.1016/s0079-6123(08)60917-6 · Cited by 41
Nakagawasai, O., Hozumi, S., Tan–No, K., Niijima, F., Arai, Y., Yasuhara, H., & Tadano, T. (2003) · Behavioural Brain Research · doi:10.1016/s0166-4328(02)00383-2 · Cited by 44
Burgos‐Ramos, E., Puebla‐Jiménez, L., & Arilla, E. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.04.036 · Cited by 43
Is ammonia a pathogenetic factor in Alzheimer's disease?
Seiler, N. (1993) · Neurochemical Research · doi:10.1007/bf00969079 · Cited by 41
“235 15), dopaminergic (9,16) and somatostatinergic (17),”
Manfridi, A., Forloni, G., Vezzani, A., Fodritto, F., & Simoni, M. G. D. (1991) · Neuroscience · doi:10.1016/0306-4522(91)90203-z · Cited by 40
Krantic, S. M., Robitaille, Y., & Quirion, R. (1992) · Brain Research · doi:10.1016/0006-8993(92)90776-6 · Cited by 45
Marshall, P. E., & Landis, D. M. D. (1985) · Brain Research · doi:10.1016/0006-8993(85)90512-8 · Cited by 40
Koob, G. F. (1987) · Springer eBooks · doi:10.1007/978-1-4613-1819-4_9 · Cited by 40
Somatomedins in aging and dementia disorders of the Alzheimer type
Sara, V. R., Hall, K. E., Enzell, K., Gardner, A., Morawski, R., & Wetterberg, L. (1982) · Neurobiology of Aging · doi:10.1016/0197-4580(82)90006-9 · Cited by 39
Epelbaum, J., Lamour, Y. A., Enjalbert, A., Hamon, M., Dutar, P., & Kordon, C. (1986) · Brain Research · doi:10.1016/0006-8993(86)90379-3 · Cited by 41
Insulin‐Like Growth Factor I Receptor Binding in Brains of Alzheimer's and Alcoholic Patients
Crews, F. T., McElhaney, R., Freund, G., Ballinger, W. E., & Raizada, M. K. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb11330.x · Cited by 39
Neuropeptides. Their Distribution and Function in the Brain
Swaab, D. F. (1982) · Progress in brain research · doi:10.1016/s0079-6123(08)64192-8 · Cited by 41
Matsuoka, N., & Aigner, T. G. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36509-7 · Cited by 42
The neurochemistry of Alzheimer type, vascular type and mixed type dementias compared
Gsell, W., Strein, I., & Riederer, P. F. (1996) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6892-9_5 · Cited by 44
Molecular and cellular biology of Alzheimer amyloid
Marotta, C. A., Majocha, R. E., & Tate, B. A. (1992) · Journal of Molecular Neuroscience · doi:10.1007/bf02919403 · Cited by 40
Jolkkonen, J., Soininen, H. S., Halonen, T., Ylinen, A., Laulumaa, V., Laakso, M. P., & Riekkinen, P. J. (1986) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.49.12.1374 · Cited by 38
Somatostatin Binding Sites in Human and Monkey Brain: Localization and Characterization
Beal, M. F., Tran, V. T., Mazurek, M. F., Chattha, G. K., & Martin, J. B. (1986) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1986.tb12976.x · Cited by 38
The gamma rhythm as a guardian of brain health
Ichim, A.-M., Bârzan, H., Moca, V. V., Nagy-Dăbâcan, A., Ciuparu, A., Hapca, A., Vervaeke, K., & Muresan, R. C. (2024) · eLife · doi:10.7554/elife.100238 · Cited by 44
Saiz‐Sanchez, D., De La Rosa‐Prieto, C., Ubeda‐Bañon, I., & Martinez‐Marcos, A. (2013) · The Anatomical Record · doi:10.1002/ar.22750 · Cited by 37
“…of different neuronal populations in AD (Perry et al., 1978; Davies, 1979; Reinikainen et al., 1990; Mattson et al., 1992), including interneurons expressing somatostatin (SOM) (Davies et al., 1980), parvalbumin (PV) (Solodkin et al., 1996), and calretinin (CR) (Fonseca and Soriano, 1995).”
BackgroundInfluentialMolecular Neurobiology of Alzheimer's Disease (Syndrome?)
Zubenko, G. S. (1997) · Harvard Review of Psychiatry · doi:10.3109/10673229709000303 · Cited by 40
Monoaminergic neurotransmitters in Alzheimer's disease
Herregodts, P., Bruyland, M., Keyser, J. D., Solheid, C., Michotte, Y. M., & Ebinger, G. (1989) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(89)90179-2 · Cited by 39
Gabriel, S. M., Bierer, L. M., Harotunian, V., Purohit, D. P., Perl, D. P., & Davis, K. L. (1993) · Neuroscience Letters · doi:10.1016/0304-3940(93)90686-f · Cited by 39
Kumar, U. (2007) · The Journal of Comparative Neurology · doi:10.1002/cne.21444 · Cited by 40
“…several neurodegenerative diseases, e.g., epilepsy, Alzheimer’s disease (AD), Huntington’s disease (HD), Parkinson’s disease (PD), and acquired immunodeficiency syndrome (AIDS) (Davies et al., 1980; Reichlin, 1983; Epelbaum, 1994; Da Cunha, 1995; Patel and Srikant, 1997; Patel, 1999; Kumar, 2005).”
Martínez, M., Frank, A., & Hernánz, Á. (1993) · Journal of Neuroimmunology · doi:10.1016/0165-5728(93)90197-7 · Cited by 39
Glycosaminoglycans in Cortical Autopsy Samples from Alzheimer Brain
Jenkins, H. G., & Bachelard, H. S. (1988) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1988.tb01135.x · Cited by 36
“Furthermore, dysfunction of indoleamine, catecholamine, and neuropeptide metabolism occurs in this disease (Davies et al., 1980; Rossor, 198 1; Benton et al., 1982; DeSouza et al., 1986).”
BackgroundDavies, C. A., Morroll, D., Prinja, D., Mann, D. M. A., & Gibbs, A. C. (1990) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(90)90057-t · Cited by 40
Anatomical distribution of somatostatin immunoreactivity in the infant brainstem
Chigr, F., Najimi, M., Leduque, P., Charnay, Y., Jordan, D., Chayvialle, J. A., Tohyama, M., & Kopp, N. (1989) · Neuroscience · doi:10.1016/0306-4522(89)90135-8 · Cited by 36
Evidence for Decreased Transport of PNMT Protein in Advanced Alzheimer's Disease
Burke, W. J., Chung, H. D., Marshall, G. L., Gillespie, K. N., & Joh, T. H. (1990) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1990.tb03448.x · Cited by 36
Iguchi, H., Chan, J. S. D., Seidah, N. G., & Chrétien, M. (1987) · Peptides · doi:10.1016/0196-9781(87)90030-1 · Cited by 36
Ontogeny of some neuropeptides in the primate brain
Hayashi, M. (1992) · Progress in Neurobiology · doi:10.1016/0301-0082(92)90021-6 · Cited by 36
Metadata
- Authors
- Davies, P., Katzman, R., & Terry, R. D.
- Affiliations
- Albert Einstein College of Medicine (US)
- Venue
- Nature
- Published
- 1980-11
- Volume
- 288
- Issue
- 5788
- Pages
- 279-280
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2034969383
- Cited by
- 882
- References
- 9
- Citations by year
- 2026: 6 · 2025: 12 · 2024: 20 · 2023: 18 · 2022: 11 · 2021: 11 · 2020: 19 · 2019: 8 · 2018: 9 · 2017: 5 · 2016: 7 · 2015: 7 · 2014: 7 · 2013: 9 · 2012: 8
- FWCI
- 25.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Keywords
- Alzheimer's disease, senile dementia of the Alzheimer type, somatostatin, somatostatin-like immunoreactivity, cerebral cortex, neuropeptides, peptidergic neurons, neurotransmitter systems, cholinergic neurons, neurofibrillary tangles, neuritic plaques
- MeSH terms
- Aged, Alzheimer Disease, Cerebral Cortex, Choline O-Acetyltransferase, Dementia, Humans, Middle Aged, Radioimmunoassay, Somatostatin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.